lncRNA-DINO靶向miR-141调控Keap1-Nrf2通路促进非小细胞肺癌化疗耐药的机制研究

doi:10.3969/j.issn.1009-976X.2022.05.009

岭南现代临床外科 ›› 2022, Vol. 22 ›› Issue (05): 480-485.DOI: 10.3969/j.issn.1009-976X.2022.05.009

lncRNA-DINO靶向miR-141调控Keap1-Nrf2通路促进非小细胞肺癌化疗耐药的机制研究

夏瑶¹, 徐蕾², 唐志贤^3,4, 谢春发³, 朱慎钰^3,*

1.赣南医学院,江西赣州341000;赣南医学院第一附属医院; 2.眼科; 3.胸心外科,江西赣州 341000;
4.赣州市心胸外科脑损伤脑保护重点实验室,江西赣州 341000

通讯作者: *朱慎钰,Email：9618082@qq.com
基金资助:
江西省教育厅科学技术研究项目（GJJ190804）

lncRNA-DINO targets miR-141 to regulate the Keap1-Nrf2 pathway to promote non-small cells study on the mechanism of chemoresistance of lung cancer cells

XIA Yao¹, XU Lei², TANG Zhi-xian^3,4, XIE Chun-fa³, ZHU Shen-yu^3,*

1. Gannan Medical College, Ganzhou, Jiangxi 341000, China;
2. Department of Ophthalmology, First Affiliated Hospital of Gannan Medical College, Ganzhou, Jiangxi 341000, China;
3. Cardiothoracic Surgery, First Affiliated Hospital of Ganzhou Medical College Ganzhou, Jiangxi 341000, China;
4. Ganzhou Key Laboratory of Brain Injury and Brain Protection, Cardiothoracic Surgery, Ganzhou, Jiangxi 341000, China

Received:2022-05-05 Online:2022-10-20 Published:2022-12-06
Contact: ZHU Shen-yu,9618082@qq.com

摘要/Abstract

摘要： 目的研究lncRNA-DINO在非小细胞肺癌（NSCLC）化疗耐药中的作用机制。方法对比耐药的和敏感的NSCLC临床标本,用RT-PCR及Western实验检测DINO、miR-141、Keap1、Nrf2的表达,探索DINO、miR-141的表达与化疗耐药的关系,其次,将A549细胞株和A549/DDP细胞株进行细胞培养,使用Trizol法提取总RNA,用LncRNA芯片对比检测两组细胞株间LncRNA的表达差异。通过在线软件（RNAhybrid）预测和计算,评估DINO与miR-141结合可能性的高低。最后将A549细胞株和A549/DDP细胞株进行细胞培养,提取总RNA,RT-PCR验证两组细胞株间的DINO、miR-141、Keap1、Nrf2、HO-1、NQO1。结果耐药的A549/DDP细胞株中DINO表达较敏感的A549细胞显著降低（P<0.05）,且DINO是通过与miR-141结合而发挥作用的。RT-PCR对比检测发现,与A549细胞相比,过表达miR-141的A549-miR-141细胞中Keap1基因表达明显下降（P<0.05）,而PTEN和MSH2表达无明显变化。与A549细胞相比,A549-miR-141细胞中Keap1基因的表达下调,而Nrf2基因和其下游HO-1、NQO1基因表达显著上调（P<0.05）。结论非小细胞肺癌中lncRNA-DINO可靶向结合miR-141,进而调控Keap1-Nrf2通路而导致细胞的化疗耐药。

关键词: 非小细胞癌, lncRNA-DINO, miRNA-141, Keapl-Nrf2, 耐药

Abstract: Objective To study the mechanism of lncRNA-DINO in chemoresistance of non-small cell lung cancer （NSCLC）. Methods compare drug-resistant and sensitive NSCLC clinical specimens, detect the expression of DINO, miR-141, Keap1 and Nrf2 by RT-PCR and Western experiment, and explore the relationship between the expression of DINO and miR-141 and chemotherapy resistance. Secondly, A549 cell line and A549 / DDP cell line were cultured, and total RNA was extracted by Trizol （Invitrogen company）, The expression difference of lncrna between the two groups of cell lines was detected by lncrna chip. Through the prediction and calculation of online software （rnahybrid）, the possibility of DINO binding with miR-141 was evaluated. Finally, A549 cell line and A549/DDP cell line were cultured. Total RNA was extracted by Trizol （Invitrogen company）. The DINO, miR-141, Keap1, Nrf2, HO-1 and NQO1 between the two groups were verified by RT-PCR. Results the expression of DINO in drug-resistant A549/DDP cell lines was significantly lower than that in sensitive A549 cells （P<; 0.05）, and DINO played a role by binding to miR-141. RT-PCR showed that compared with A549 cells, the expression of Keap1 gene in a549-mir-141 cells overexpressing miR-141 decreased significantly （P<; 0.05）, while the expression of PTEN and MSH2 did not change significantly. Compared with A549 cells, the expression of Keap1 gene was down-regulated in a549-mir-141 cells, while the expression of Nrf2 gene and its downstream HO-1 and NQO1 genes were significantly up-regulated （P<; 0.05）. Conclusion In non-small cell lung cancer, lncRNA-DINO can target and bind miR-141, and then regulate keap1-nrf2 pathway, resulting in chemoresistance.

Key words: non-small cell carcinoma, lncRNA-DINO, miRNA-141, Keapl-Nrf2, Drug resistance

中图分类号:

R734.2

夏瑶, 徐蕾, 唐志贤, 谢春发, 朱慎钰. lncRNA-DINO靶向miR-141调控Keap1-Nrf2通路促进非小细胞肺癌化疗耐药的机制研究[J]. 岭南现代临床外科, 2022, 22(05): 480-485.

XIA Yao, XU Lei, TANG Zhi-xian, XIE Chun-fa, ZHU Shen-yu. lncRNA-DINO targets miR-141 to regulate the Keap1-Nrf2 pathway to promote non-small cells study on the mechanism of chemoresistance of lung cancer cells[J]. Lingnan Modern Clinics In Surgery, 2022, 22(05): 480-485.

参考文献

[1] Byers T, Wender RC, Jemal A, et al.The American Cancer Society challenge goal to reduce US cancer mortality by 50% between 1990 and 2015: results and reflections[J]. CA Cancer J Clin, 2016, 66(5): 359-369.
[2] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J].CA Cancer J Clin, 2016, 66(2): 115-132.
[3] Chen XZ, Liu Y, Wang R, et al.Improvement of cancer control in mainland China: epidemiological profiles during the 2004-10 National Cancer Prevention and Control Program[J]. Lancet, 2016, 388: S40.
[4] Baghdadi M, Wada H, Nakanishi S, et al.Chemotherapy-induced IL34 enhances immunosuppression by tumor-associated macrophages and mediates survival of chemoresistant lung cancer cells[J]. Cancer Res, 2016, 76(20): 6030-6042.
[5] Matsumoto A, Pasut A, Matsumoto M, et al.mTORC1 and muscle regeneration are regulated by the LINC00961-encoded SPAR polypeptide[J]. Nature, 2017, 541(7636): 228-232.
[6] Schmitt AM, Chang HY.Long noncoding RNAs in cancer pathways[J]. Cancer Cell, 2016, 29(4): 452-463.
[7] Liu SJ, Horlbeck MA, Cho SW, et al. CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells [J]. Science, 2017, 355(6320): eaah7111.
[8] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[9] Fitzmaurice C, Abate D, Abbasi N, et al.Global, regional and national cancer incidence, mortality, years of life lost years lived with disability, and disability-adjusted life years for 29 cancer groups, 1990 to 2017: A systematic analysis for the global burden of disease study[J]. JAMA Oncol,2018,4(11):1153-1168.
[10] Schmitt AM, Garcia JT, Hung T, et al.An inducible long noncoding RNA amplifies DNA damage signaling[J]. Nat Genet, 2016, 48(11): 1370-1376.
[11] Du Z, Sun T, Hacisuleyman E, et al.Integrative analyses reveal a long noncoding RNA-mediated sponge regulatory network in prostate cancer[J]. Nat Comm, 2016, 7(1): 1-10.
[12] Chen L, Gibbons DL, Goswami S, et al.Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression[J].Nat Commun, 2014, 5(1): 1-12.
[13] Kundu ST, Byers LA, Peng DH, et al.The miR-200 family and the miR-183~ 96~ 182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers[J]. Oncogene, 2016, 35(2): 173-186.
[14] Yao YS, Qiu WS, Yao RY, et al.miR-141 confers docetaxel chemoresistance of breast cancer cells via regulation of EIF4E expression[J]. Oncol Rep, 2015, 33(5): 2504-2512.
[15] Brozovic A, Duran GE, Wang YC, et al.The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells[J]. Mol Oncol, 2015, 9(8): 1678-1693.
[16] Bell KFS, Al-Mubarak B, Martel MA, et al.Neuronal development is promoted by weakened intrinsic antioxidant defences due to epigenetic repression of Nrf2[J]. Nat Commun, 2015, 6(1): 1-15.
[17] Lu MC, Ji JA, Jiang ZY, et al.The Keap1-Nrf2-ARE pathway as a potential preventive and therapeutic target: an update[J]. Med Res Rev, 2016, 36(5): 924-963.
[18] Jeong Y, Hoang NT, Lovejoy A, et al.Role of KEAP1/NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiation resistance[J]. Cancer Discov, 2017, 7(1): 86-101.
[19] Oshimori N, Oristian D, Fuchs E.TGF-β promotes heterogeneity and drug resistance in squamous cell carcinoma[J]. Cell, 2015, 160(5): 963-976.
[20] Guan L, Zhang L, Gong Z, et al.FoxO3 inactivation promotes human cholangiocarcinoma tumorigenesis and chemoresistance through Keap1-Nrf2 signaling[J]. Hepatology, 2016, 63(6): 1914-1927.

lncRNA-DINO靶向miR-141调控Keap1-Nrf2通路促进非小细胞肺癌化疗耐药的机制研究

lncRNA-DINO targets miR-141 to regulate the Keap1-Nrf2 pathway to promote non-small cells study on the mechanism of chemoresistance of lung cancer cells

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 10

编辑推荐

Metrics

[1]	黄赛林, 许绍强, 范艳丽, 李莲, 郑涛, 时宏治. 神经外科住院患者医院获得性感染病原菌结果回顾性分析[J]. 岭南现代临床外科, 2022, 22(01): 84-88.
[2]	桂秀娟, 赵健丽, 汪颖, 柴洁, 丁林潇潇, 姚和瑞. 伊尼妥单抗联合吡咯替尼治疗HER2阳性晚期乳腺癌1例[J]. 岭南现代临床外科, 2021, 21(06): 675-678.
[3]	彭江云, 姚伟城, 王永强, 邓伟溪. HER2阳性乳腺癌治疗及耐药性研究进展[J]. 岭南现代临床外科, 2020, 20(02): 243-253.
[4]	张华耀，谭浪平，刘建平，苏正，韦金星，黄延年*. 小干扰RNA逆转Wnt/β-catenin通路对肝癌耐药细胞株HepG2/ADM的影响研究[J]. 岭南现代临床外科, 2019, 19(05): 520-524.
[5]	雷瑞霖，张萌，蒋小燕，陈思琪，林荣春*. 卵巢癌铂耐药患者肿瘤组织中LINC01151的表达及诊断效能研究[J]. 岭南现代临床外科, 2019, 19(05): 563-566.
[6]	吴祥曾柏强冉义洪张红卫. SH3GL1与p?ERK在原发性肝癌中的表达与其对索拉非尼治疗效果的影响[J]. 岭南现代临床外科, 2017, 17(03): 255-260.
[7]	吴斌. 青少年尿路感染细菌分布以及耐药性分析[J]. 岭南现代临床外科, 2016, 16(04): 457-459.
[8]	杨克戈黄开红. RKIP在肿瘤中的研究进展[J]. 岭南现代临床外科, 2015, 15(04): 513-516.
[9]	叶露陈劲峰潘景升王建蔡卫平郑海鹏李高鹏. 艾滋病与非艾滋病患者铜绿假单胞菌感染临床及耐药对比研究[J]. 岭南现代临床外科, 2014, 14(06): 694-697.
[10]	于江龙兰世英. 神经外科重症监护病房万古霉素耐药性肠球菌感染的发生率及危险因素分析[J]. 岭南现代临床外科, 2014, 14(04): 462-465.